Get started
Author

Pere Gascón Vilaplana

Observed names: P. Gascón Vilaplana, Pere Gascon Vilaplana
OpenAlex ID: A5111670055
Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study
2017 · R. López López, C. Camps Herrero, et al. · Clinical & Translational Oncology · 24
Clinical practice guidelines on antiemetics in oncology
2005 · Enrique Aranda Aguilar, Manuel Constenla Figueiras, et al. · Expert Review of Anticancer Therapy · 12
Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)
2008 · Enric Carcereny Costa, Núria Viñolas Segarra, et al. · Clinical & Translational Oncology · 4
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients
2009 · Vicente Alberola Candel, Alfredo Carrato Mena, et al. · Clinical & Translational Oncology · 3
1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC)
2003 · E. Van Cutsem, P. Gascón Vilaplana, et al. · European Journal of Cancer Supplements · 3
Polseres vermelles y el cáncer
2016 · Pere Gascón Vilaplana · RACO (Revistes Catalanes amb Accés Obert) (Consorci de Serveis Universitaris de Catalunya)
PDF
El concepte de Neurohematopoesi: Importància per a la fisiologia de la sang i del procés metastàsic
2013 · Pere Gascón Vilaplana · RACO (Revistes Catalanes amb Accés Obert) (Consorci de Serveis Universitaris de Catalunya)
PDF
Marcadores tumorales en cáncer de cabeza y cuello y su utilidad clínica
2007 · Pere Gascón Vilaplana · Medicina Clínica
HER2-positive breast cancer cells percentage and progression to trastuzumab treatment in metastatic patients
2007 · Y. García-García, A. Martínez-Fernández, et al. · Journal of Clinical Oncology
Works count: 9
Citation count: 46
H-index: 3
I10-index: 2
Year
Topic
Type